Aardvark Therapeutics, Inc. Common Stock (NASDAQ:AARD) — Market Cap & Net Worth
Market Cap & Net Worth: Aardvark Therapeutics, Inc. Common Stock (AARD)
Aardvark Therapeutics, Inc. Common Stock (NASDAQ:AARD) has a market capitalization of $120.41 Million ($120.41 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #18585 globally and #4323 in its home market, demonstrating a 12.40% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Aardvark Therapeutics, Inc. Common Stock's stock price $5.53 by its total outstanding shares 21773272 (21.77 Million). Also see AARD total assets for a full breakdown of the balance sheet.
Aardvark Therapeutics, Inc. Common Stock Market Cap History: 2025 to 2026
Aardvark Therapeutics, Inc. Common Stock's market capitalization history from 2025 to 2026. Data shows change from $285.77 Million to $120.41 Million (-42.44% CAGR). Also see Aardvark Therapeutics, Inc. Common Stock (AARD) cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Aardvark Therapeutics, Inc. Common Stock is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #522 of 976 |
Weight: Aardvark Therapeutics, Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Aardvark Therapeutics, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Aardvark Therapeutics, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check AARD share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of AARD by Market Capitalization
Companies near Aardvark Therapeutics, Inc. Common Stock in the global market cap rankings as of September 18, 2026. Review Aardvark Therapeutics, Inc. Common Stock (AARD) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Aardvark Therapeutics, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Aardvark Therapeutics, Inc. Common Stock Historical Marketcap From 2025 to 2026
Between 2025 and today, Aardvark Therapeutics, Inc. Common Stock's market cap moved from $285.77 Million to $ 120.41 Million, with a yearly change of -42.44%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $120.41 Million | -57.87% |
| 2025 | $285.77 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Aardvark Therapeutics, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $120.41 Million USD |
| MoneyControl | $120.41 Million USD |
| MarketWatch | $120.41 Million USD |
| marketcap.company | $120.41 Million USD |
| Reuters | $120.41 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Aardvark Therapeutics, Inc. Common Stock
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen, which is in the Phase 3 clinical trial… Read more